Skip to main content
. Author manuscript; available in PMC: 2018 Jan 11.
Published in final edited form as: Clin Cancer Res. 2016 Jul 11;23(3):746–756. doi: 10.1158/1078-0432.CCR-16-1021

Figure 4. Longitudinal analysis of patients with CRPC.

Figure 4

(A) Pt 40, and (B) Pt 36 were monitored as they progressed through the indicated treatments. Treatment is indicated at the top. The initial blood draw (Month 0) corresponds to (A) cycle 3 of chemohormonal therapy for Pt 40 and (B) cycle 2 of Enzalutamide treatment for Pt 36. For each patient, and at each time point, we present AR nuclear localization verses intensity (each point representing a single CTC). Below each plot, we show panels with gene expression data (represented as a heat map of Ct values). CAB (Combined Androgen Blockade), AAWD (Anti-Androgen Withdrawl)